2:15
Ben Jones on the Impact of Sequestration on Reimbursement
Ben Jones, Senior Director of Government Relations & Public Policy at McKesson Specialty H...
published: 05 Aug 2013
Ben Jones on the Impact of Sequestration on Reimbursement
Ben Jones on the Impact of Sequestration on Reimbursement
Ben Jones, Senior Director of Government Relations & Public Policy at McKesson Specialty Health & The US Oncology Network, discusses the impact of sequestration on drug and physician reimbursement. More from OncLiveTV: http://www.onclive.com/onclive-tv- published: 05 Aug 2013
- views: 40
1:43
Dr. Schneiderman on Cancer Drugs and Futility Policies
Lawrence J. Dr. Schneiderman on Cancer Drugs and Futility Policies, MD, professor emeritu...
published: 18 Mar 2014
Dr. Schneiderman on Cancer Drugs and Futility Policies
Dr. Schneiderman on Cancer Drugs and Futility Policies
Lawrence J. Dr. Schneiderman on Cancer Drugs and Futility Policies, MD, professor emeritus, Medicine/Family & Preventive Medicine, University of California, San Diego (UCSD), discusses futility policies in relation to cancer drugs. More from OncLive TV: http://onclivetv.com- published: 18 Mar 2014
- views: 26
1:33
Dr. Vincent Miller Describes FoundationOne
Vincent Miller, MD, Chief Medical Officer, Foundation Medicine, describes the FoundationOn...
published: 18 Feb 2014
Dr. Vincent Miller Describes FoundationOne
Dr. Vincent Miller Describes FoundationOne
Vincent Miller, MD, Chief Medical Officer, Foundation Medicine, describes the FoundationOne, a fully informative genomic profile that launched in 2012. More from OncLive TV: http://www.onclive.com/onclive-tv- published: 18 Feb 2014
- views: 34
1:39
Dr. Howard L. Kaufman on the Implications of the Immunoscore
Howard L. Kaufman, MD, Rush University Medical Center, discusses the implications of the I...
published: 16 Jul 2013
Dr. Howard L. Kaufman on the Implications of the Immunoscore
Dr. Howard L. Kaufman on the Implications of the Immunoscore
Howard L. Kaufman, MD, Rush University Medical Center, discusses the implications of the Immunoscore for the treatment of patients with cancer. More from OncLiveTV: http://www.onclive.com/onclive-tv- published: 16 Jul 2013
- views: 11
1:12
Dr. Hudis Discusses Obesity as a Modifiable Risk Factor for Cancer
Clifford A. Hudis, MD, ASCO President-Elect and chief of the Breast Cancer Medicine Servic...
published: 06 Aug 2013
Dr. Hudis Discusses Obesity as a Modifiable Risk Factor for Cancer
Dr. Hudis Discusses Obesity as a Modifiable Risk Factor for Cancer
Clifford A. Hudis, MD, ASCO President-Elect and chief of the Breast Cancer Medicine Service and attending physician at Memorial Sloan-Kettering Cancer Center, discusses obesity as a modifiable risk factor for cancer. More from OncLiveTV: http://www.onclive.com/onclive-tv- published: 06 Aug 2013
- views: 5
1:07
Dr. Partridge on the Adult Survivorship Program at Dana-Farber Cancer Institute
Ann H. Partridge, MD, MPH, from the Dana-Farber Cancer Institute, gives an overview of the...
published: 28 Jun 2013
author: OncLiveTV
Dr. Partridge on the Adult Survivorship Program at Dana-Farber Cancer Institute
Dr. Partridge on the Adult Survivorship Program at Dana-Farber Cancer Institute
Ann H. Partridge, MD, MPH, from the Dana-Farber Cancer Institute, gives an overview of the Adult Survivorship Program. For more from OncLiveTV: http://www.on...- published: 28 Jun 2013
- views: 2
- author: OncLiveTV
1:18
Dr. Donato Discusses the National Marrow Donor Program
Michele L. Donato, MD, medical director, Blood and Marrow Collection Facility, John Theure...
published: 08 May 2014
Dr. Donato Discusses the National Marrow Donor Program
Dr. Donato Discusses the National Marrow Donor Program
Michele L. Donato, MD, medical director, Blood and Marrow Collection Facility, John Theurer Cancer Center, provides an overview of the National Marrow Donor Program (NMDP). More from OncLiveTV: http://www.onclive.com/onclive-tv- published: 08 May 2014
- views: 4
0:45
Dr. Gogineni Comments on Oncology Drug Shortages
Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of...
published: 11 Jul 2013
author: OncLiveTV
Dr. Gogineni Comments on Oncology Drug Shortages
Dr. Gogineni Comments on Oncology Drug Shortages
Keerthi Gogineni, MD, MSHP, medical oncologist, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, comments on oncology drug sh...- published: 11 Jul 2013
- views: 4
- author: OncLiveTV
0:56
Dr. Van Tine Discusses Identifying Biomarkers in Sarcomas
Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine ...
published: 12 Aug 2013
author: OncLiveTV
Dr. Van Tine Discusses Identifying Biomarkers in Sarcomas
Dr. Van Tine Discusses Identifying Biomarkers in Sarcomas
Brian A. Van Tine, MD, PhD, Assistant Professor, Washington University School of Medicine in St. Louis, discusses identifying biomarkers in sarcomas. More fr...- published: 12 Aug 2013
- views: 1
- author: OncLiveTV
1:13
Dr. Bradley on the Agonist OX40 for the Treatment of Cancer
Edward Bradley, MD, Senior Vice President, Head, Innovative Medicines unit (iMED), MedImmu...
published: 28 Aug 2013
Dr. Bradley on the Agonist OX40 for the Treatment of Cancer
Dr. Bradley on the Agonist OX40 for the Treatment of Cancer
Edward Bradley, MD, Senior Vice President, Head, Innovative Medicines unit (iMED), MedImmune (the global biologics research and development arm of AstraZeneca), describes the development of an agonist for the treatment of cancer. For more from OncLiveTV, visit: http://www.onclive.com/onclive-tv- published: 28 Aug 2013
- views: 5
1:16
Dr. Brahmer on Distinguishing Between Immunotherapy Response and Cancer Growth
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comp...
published: 30 Oct 2013
Dr. Brahmer on Distinguishing Between Immunotherapy Response and Cancer Growth
Dr. Brahmer on Distinguishing Between Immunotherapy Response and Cancer Growth
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses how physicians distinguish between a response to an immunotherapy and cancer growth. More from OncLiveTV: http://www.onclive.com/onclive-tv- published: 30 Oct 2013
- views: 5
2:01
Dr. Estey Discusses the FDA Approval Process
Elihu H. Estey, MD, professor of medicine, University of Washington School of Medicine, Fr...
published: 18 Dec 2013
Dr. Estey Discusses the FDA Approval Process
Dr. Estey Discusses the FDA Approval Process
Elihu H. Estey, MD, professor of medicine, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, discusses a potential change to the FDA approval process as it relates to Mylotarg (gemtuzumab ozogamicin). More from OncLive TV: http://www.onclive.com/onclive-tv- published: 18 Dec 2013
- views: 11
1:40
Dr. Adjei on Adverse Events From MEK Inhibitors
Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia ...
published: 11 Sep 2013
Dr. Adjei on Adverse Events From MEK Inhibitors
Dr. Adjei on Adverse Events From MEK Inhibitors
Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses eye toxicity from MEK inhibitors. More from OncLiveTV: http://www.onclive.com/onclive-tv- published: 11 Sep 2013
- views: 0
1:08
Dr. Rapoport Discusses Hyponatremia in Patients With Cancer
Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Lang...
published: 22 Nov 2013
Dr. Rapoport Discusses Hyponatremia in Patients With Cancer
Dr. Rapoport Discusses Hyponatremia in Patients With Cancer
Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, discusses hyponatremia in patients with cancer. More from OncLive TV: http://www.onclive.com/onclive-tv- published: 22 Nov 2013
- views: 9
Youtube results:
1:46
Dr. Goy Comments on Recent Developments in the Field of Immunology
Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, ...
published: 14 Aug 2013
author: OncLiveTV
Dr. Goy Comments on Recent Developments in the Field of Immunology
Dr. Goy Comments on Recent Developments in the Field of Immunology
Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, comments on the recent developments in fighting cancer with the imm...- published: 14 Aug 2013
- views: 1
- author: OncLiveTV
1:30
Dr. Brahmer Discusses the Management of Adverse Events From Immunotherapy
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comp...
published: 26 Sep 2013
Dr. Brahmer Discusses the Management of Adverse Events From Immunotherapy
Dr. Brahmer Discusses the Management of Adverse Events From Immunotherapy
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the management of adverse events (AEs) from treatment with immunotherapies. More from OncLiveTV: http://www.onclive.com/onclive-tv- published: 26 Sep 2013
- views: 11
1:20
Dr. Hudis on the Optimism Surrounding Immunotherapy
Clifford A. Hudis, MD, ASCO President, Chief, Breast Cancer Medicine Service, Attending Ph...
published: 26 Sep 2013
Dr. Hudis on the Optimism Surrounding Immunotherapy
Dr. Hudis on the Optimism Surrounding Immunotherapy
Clifford A. Hudis, MD, ASCO President, Chief, Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care. More from OncLiveTV: http://www.onclive.com/onclive-tv- published: 26 Sep 2013
- views: 12
1:09
Dr. Carvajal on the Investigation of Selumetinib for Uveal Melanoma
Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discu...
published: 25 Jul 2013
author: OncLiveTV
Dr. Carvajal on the Investigation of Selumetinib for Uveal Melanoma
Dr. Carvajal on the Investigation of Selumetinib for Uveal Melanoma
Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses the background of the investigation of selumetinib for advance...- published: 25 Jul 2013
- views: 11
- author: OncLiveTV